{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:01:29Z","timestamp":1762480889346,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.gore.2022.101005","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T02:13:41Z","timestamp":1654222421000},"page":"101005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Expression of CD44+\/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study"],"prefix":"10.1016","volume":"42","author":[{"given":"Unedo Hence Markus","family":"Sihombing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Andrijono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gatot","family":"Purwoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriadi","family":"Gandamihardja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alida R.","family":"Harahap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Primariadewi","family":"Rustamadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aria","family":"Kekalih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Retno","family":"Widyawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dzicky Rifqi","family":"Fuady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gore.2022.101005_b0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.gore.2022.101005_b0010","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl. J. Med."},{"issue":"27","key":"10.1016\/j.gore.2022.101005_b0015","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.19.00022","article-title":"Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer","volume":"37","author":"du Bois","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.gore.2022.101005_b0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10585-012-9482-4","article-title":"CD44+\/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival","volume":"29","author":"Meng","year":"2012","journal-title":"Clin. Exp. Metastasis."},{"key":"10.1016\/j.gore.2022.101005_b0025","doi-asserted-by":"crossref","unstructured":"Zhenhua Hu JG, Danye Zhang, Qing Liu, Limei Yan, Lili Gao, Juanjuan Liu, Dawo Liu, Shulan Zhang, Bei Lin. High Expression of Lewis y Antigen and CD44 Is Correlated with Resistance to Chemotherapy in Epithelial Ovarian Cancers. PloS one. 2013;8(2).","DOI":"10.1371\/journal.pone.0057250"},{"key":"10.1016\/j.gore.2022.101005_b0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2020.01.008","article-title":"DNA damage response and resistance of cancer stem cells","volume":"474","author":"Abad","year":"2020","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.gore.2022.101005_b0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbrc.2015.11.134","article-title":"Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer","volume":"469","author":"Somasagara","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.gore.2022.101005_b0040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1541-7786.MCR-13-0638","article-title":"DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer","volume":"12","author":"Han","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"78","key":"10.1016\/j.gore.2022.101005_b0045","doi-asserted-by":"crossref","first-page":"34708","DOI":"10.18632\/oncotarget.26168","article-title":"DDB2 regulates Epithelial-to-Mesenchymal Transition (EMT) in Oral\/Head and Neck Squamous Cell Carcinoma","volume":"9","author":"Bommi","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.gore.2022.101005_b0050","doi-asserted-by":"crossref","unstructured":"Alberts B JA, lewis J, Morgan D, Raff M, Robert K, Walter P. Molecular Biology of the Cell (6 edition) 6 th ed: Garland Science; 2008.","DOI":"10.1201\/9780203833445"},{"issue":"48","key":"10.1016\/j.gore.2022.101005_b0055","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/onc.2017.279","article-title":"RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance","volume":"36","author":"Somasagara","year":"2017","journal-title":"Oncogene."},{"issue":"9","key":"10.1016\/j.gore.2022.101005_b0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","article-title":"Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target","volume":"4","author":"Yan","year":"2015","journal-title":"Stem cells Transl. Med."},{"issue":"4","key":"10.1016\/j.gore.2022.101005_b0065","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1053\/j.gastro.2013.12.035","article-title":"Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology."},{"issue":"3","key":"10.1016\/j.gore.2022.101005_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.72","article-title":"A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity","volume":"8","author":"Hu","year":"2017","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.gore.2022.101005_b0075","first-page":"5059","article-title":"Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Experim. Med."},{"issue":"5","key":"10.1016\/j.gore.2022.101005_b0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.urolonc.2014.01.001","article-title":"Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy","volume":"32","author":"Hofner","year":"2014","journal-title":"Urol. Oncol. Seminars Original Investigations"},{"key":"10.1016\/j.gore.2022.101005_b0085","doi-asserted-by":"crossref","unstructured":"Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z, et al. The prognostic and clinical value of CD44 in colorectal cancer: a meta-analysis. Frontiers in oncology. 2019;9:309.","DOI":"10.3389\/fonc.2019.00309"},{"issue":"6","key":"10.1016\/j.gore.2022.101005_b0090","first-page":"5351","article-title":"Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.gore.2022.101005_b0095","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e32","article-title":"Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism","volume":"29","author":"Li","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2022.101005_b0100","first-page":"1","article-title":"Unraveling the roles of CD44\/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.gore.2022.101005_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-13-62","article-title":"Increased invasion and tumorigenicity capacity of CD44+\/CD24-breast cancer MCF7 cells in vitro and in nude mice","volume":"13","author":"Yan","year":"2013","journal-title":"Cancer Cell Int."},{"issue":"18","key":"10.1016\/j.gore.2022.101005_b0110","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/onc.2010.35","article-title":"CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells","volume":"29","author":"Gao","year":"2010","journal-title":"Oncogene."},{"key":"10.1016\/j.gore.2022.101005_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00039","article-title":"Prognostic value of CD44 and its isoforms in advanced cancer: a systematic meta-analysis with trial sequential analysis","volume":"9","author":"Han","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gore.2022.101005_b0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2016.04.196","article-title":"Rad6 inhibition sensitizes ovarian cancer cells to platinum drugs by attenuating activation of multiple DNA repair networks","volume":"141","author":"Spencer","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2022.101005_b0125","doi-asserted-by":"crossref","first-page":"e1392403","DOI":"10.1080\/23723556.2017.1392403","article-title":"RAD6 promotes chemoresistance in ovarian cancer","volume":"5","author":"Clark","year":"2018","journal-title":"Mol. Cellular Oncol."},{"key":"10.1016\/j.gore.2022.101005_b0130","article-title":"RAD6-mediated epigenetic reprogramming contributes to therapy-induced chemo-resistance in ovarian cancer","author":"Omy","year":"2021","journal-title":"AACR"},{"issue":"1","key":"10.1016\/j.gore.2022.101005_b0135","doi-asserted-by":"crossref","first-page":"165561","DOI":"10.1016\/j.bbadis.2019.165561","article-title":"RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis\/Fanconi anemia crosstalk and BRCA1 independence","volume":"1866","author":"Haynes","year":"2020","journal-title":"Biochim. et Biophys. Acta (BBA)-Mol. Basis Dis."},{"issue":"6","key":"10.1016\/j.gore.2022.101005_b0140","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.3892\/ol.2016.5237","article-title":"UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells","volume":"12","author":"Gong","year":"2016","journal-title":"Oncol. Lett."},{"issue":"20","key":"10.1016\/j.gore.2022.101005_b0145","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.3390\/ijms20205168","article-title":"Emerging roles of DDB2 in cancer","volume":"20","author":"Gilson","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.gore.2022.101005_b0150","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1074\/jbc.M111.295816","article-title":"p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies","volume":"287","author":"Stoyanova","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gore.2022.101005_b0155","doi-asserted-by":"crossref","unstructured":"Kattan Z, Marchal S, Brunner E, Ramacci C, Leroux A, Merlin JL, et al. Damaged DNA binding protein 2 plays a role in breast cancer cell growth. PloS one. 2008;3(4):e2002.","DOI":"10.1371\/journal.pone.0002002"},{"issue":"11","key":"10.1016\/j.gore.2022.101005_b0160","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1007\/s10620-018-5224-z","article-title":"Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer","volume":"63","author":"Yang","year":"2018","journal-title":"Digest. Dis. Sci."},{"key":"10.1016\/j.gore.2022.101005_b0165","first-page":"NA","article-title":"Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis","author":"Barakat","year":"2010","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.gore.2022.101005_b0170","article-title":"Loss of DDB2 enhances the tumorigenicity of ovarian cancer cells through expanding cancer stem-like cell population","author":"Han","year":"2014","journal-title":"AACR"},{"issue":"10","key":"10.1016\/j.gore.2022.101005_b0175","doi-asserted-by":"crossref","first-page":"14183","DOI":"10.1007\/s13277-016-5203-y","article-title":"DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses","volume":"37","author":"Zou","year":"2016","journal-title":"Tumor Biol."},{"issue":"7","key":"10.1016\/j.gore.2022.101005_b0180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4252\/wjsc.v11.i7.383","article-title":"Presence and role of stem cells in ovarian cancer","volume":"11","author":"Suster","year":"2019","journal-title":"World J. Stem Cells."},{"key":"10.1016\/j.gore.2022.101005_b0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biocel.2018.11.012","article-title":"Ovarian cancer stem cells and their role in drug resistance","volume":"106","author":"Pieterse","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578922000856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578922000856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:56:40Z","timestamp":1762480600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578922000856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":37,"alternative-id":["S2352578922000856"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2022.101005","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of CD44+\/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2022.101005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101005"}}